Selinexor and Melphalan for high-risk AML after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is for people age 55 and older with high-risk acute myeloid leukemia (AML) who have already had a stem cell transplant. It tests a new combination of two drugs, Selinexor and Melphalan, given twice a week to help prevent the leukemia from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older.
- You have a type of acute myeloid leukemia (AML) that is considered high-risk (not APL).
- You have already received a stem cell transplant from a donor.
- Your leukemia was in complete remission (no signs of disease) right before your transplant.
- You are able to take care of most of your daily activities (Karnofsky score of 60 or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like MDS, AML, or CMML, especially those who have leftover leukemia cells before a stem cell transplant. The goal is to see if this treatment can improve outcomes.
This trial tests a new combination of two chemotherapy drugs, melphalan and cladribine, given before a stem cell transplant. It is designed for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.